EFM
APGE icon

E Fund Management’s Apogee Therapeutics APGE Stock Holding History

E Fund Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$625K Sell
4,706
-2,887
-38% -$260K 0.01% 226
2026
Q1 		$639K Buy
+7,593
New +$551K 0.02% 230
2025
Q2 		$204K Buy
+4,700
New +$179K 0.01% 359
2024
Q4 		– Sell
-3,506
Closed -$206K – 397
2024
Q3 		$206K Buy
+3,506
New +$168K 0.01% 328
2024
Q2 		– Sell
-3,125
Closed -$208K – 322
2024
Q1 		$208K Buy
+3,125
New +$136K 0.01% 338

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

E Fund Management's APGE Position: Q2 2026 in Review

E Fund Management reduced its Apogee Therapeutics (APGE) stake by 38% in Q2 2026, selling an estimated $260K and leaving 4,706 shares worth $625K. The position accounts for 0.01% of the portfolio, ranked #226.

E Fund Management first reported a position in APGE in Q1 2024 and has held it in 5 quarters since. The position peaked at $639K in Q1 2026. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • E Fund Management held 4,706 shares of Apogee Therapeutics worth $625K as of Q2 2026.
  • E Fund Management sold 2,887 Apogee Therapeutics shares in Q2 2026, an estimated $260K.
  • Apogee Therapeutics made up 0.01% of E Fund Management's portfolio in Q2 2026, its #226 holding.
  • E Fund Management first reported a position in Apogee Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • E Fund Management's Apogee Therapeutics position peaked at $639K in Q1 2026.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.